Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide-Reference-Cited by-同舟云学术

Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide

Published:2021-12 Issue: Volume: Page:
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Lai Lillian Y.^ORCID,Oerline Mary K.^ORCID,Kaufman Samuel R.,Herrel Lindsey A.,Skolarus Ted A.,Dusetzina Stacie B.^ORCID,Ellimoottil Chad,Shahinian Vahakn B.,Hollenbeck Brent K.,Caram Megan E.V.

Funder

Agency for Healthcare Research and Quality

National Cancer Institute

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. American Cancer Society. Key statistics for prostate cancer. 2021. Available at: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed March 14, 2021

2. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

3. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan;Oncology;2024-08-14

2. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019;International Urogynecology Journal;2023-02-01

3. Trends in Industry Payments to Physicians in the First 6 Years After Graduate Medical Training;JAMA Network Open;2022-10-19